NEW YORK (GenomeWeb News) — The National Cancer Institute is looking to license or co-develop a microRNA sequence that it said can enhance the capacity of T-lymphocytes to recognize tumors in several kinds of cancer, according to the National Institutes of Health.
 
NIH said the technology, listed under patent application No. 60/940,172, is the “first reported use” of an miRNA gene to treat disease.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

The Wall Street Journal looks into the cost of new gene therapies.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.